Find therapies in clinical trials near you – page 67

Study on Brigatinib for Patients with ALK+ Non-Small Cell Lung Cancer

Study on Brigatinib for Patients with ALK+ Non-Small Cell Lung Cancer

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Study on Skin Care for Patients with Advanced EGFR-Mutated Lung Cancer Treated with Amivantamab and Lazertinib

Study on Skin Care for Patients with Advanced EGFR-Mutated Lung Cancer Treated with Amivantamab and Lazertinib

Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

Study of Pembrolizumab, Lenvatinib, and Chemotherapy for First-Line Treatment in Extensive-Stage Small Cell Lung Cancer Patients

Study of Pembrolizumab, Lenvatinib, and Chemotherapy for First-Line Treatment in Extensive-Stage Small Cell Lung Cancer Patients